Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
acetylcysteine + pyridoxamine
- Development stage
- Unknown
- Lead developer
- Primus Remedies
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Nephroheal Forte is a fixed-dose combination of acetylcysteine (300 mg) and pyridoxamine dihydrochloride (50 mg), developed by Primus Remedies for the management of chronic kidney disease (CKD), particularly diabetic nephropathy. Acetylcysteine is a precursor to the endogenous antioxidant glutathione, which helps neutralize free radicals, reduce oxidative stress, and protect renal tissues from cellular damage. Pyridoxamine, a bioactive form of vitamin B6, acts as an inhibitor of advanced glycation end-products (AGEs) and advanced lipoxidation end-products (ALEs) by chelating catalytic transition metals and trapping reactive carbonyl species. Together, these components work synergistically to slow the progression of kidney damage, support metabolic processes, and preserve renal function in patients with CKD.
- Brand names
- Nephroheal Forte
- Other names
- N-acetylcysteine + pyridoxamineN-acetylcysteine + pyridoxamine dihydrochlorideNAC + pyridoxamineNAC + pyridoxamine dihydrochlorideacetylcysteine + pyridoxamineacetylcysteine + pyridoxamine dihydrochloride
02
Targets
THTR (Thiamine transporter 1)
Beyond the preview
Go deeper on acetylcysteine + pyridoxamine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on acetylcysteine + pyridoxamine.